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Abstract
Background: The liver has been suggested as a suitable target organ for gene therapy of Type 1
diabetes. However, the fundamental issue whether insulin-secreting hepatocytes in vivo will be
destroyed by the autoimmune processes that kill pancreatic β cells has not been fully addressed. It
is possible that the insulin secreting liver cells will be destroyed by the immune system because
hepatocytes express major histocompatibility complex (MHC) class I molecules and exhibit
constitutive Fas expression; moreover the liver has antigen presenting activity. Together with
previous reports that proinsulin is a possible autoantigen in the development of Type 1 diabetes,
the autoimmune destruction of insulin producing liver cells is a distinct possibility.
Methods: To address this question, transgenic Non-Obese Diabetic (NOD) mice which express
insulin in the liver were made using the Phosphoenolpyruvate Carboxykinase (PEPCK) promoter
to drive the mouse insulin I gene (Ins).
Results: The liver cells were found to possess preproinsulin mRNA, translate (pro)insulin in vivo
and release it when exposed to 100 nmol/l glucagon in vitro. The amount of insulin produced was
however significantly lower than that produced by the pancreas. The transgenic PEPCK-Ins NOD
mice became diabetic at 20–25 weeks of age, with blood glucose levels of 24.1 ± 1.7 mmol/l.
Haematoxylin and eosin staining of liver sections from these transgenic NOD PEPCK-Ins mice
revealed the absence of an infiltrate of immune cells, a feature that characterised the pancreatic
islets of these mice.
Conclusions: These data show that hepatocytes induced to produce (pro)insulin in NOD mice
are not destroyed by an ongoing autoimmune response; furthermore the expression of (pro)insulin
in hepatocytes is insufficient to prevent development of diabetes in NOD mice. These results
support the use of liver cells as a potential therapy for type 1 diabetes. However it is possible that
a certain threshold level of (pro)insulin production might have to be reached to trigger the
autoimmune response.
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Background
Genetic alteration of non-pancreatic cells in a diabetic
person to synthesise, store and secrete insulin in the same
manner as a pancreatic β cell is a potential therapy of type
1 diabetes. The hepatocyte has been suggested as a suita-
ble target cell for such gene therapy [1-9]. Such cells made
in vitro are capable of synthesizing and storing pro(insu-
lin) and can secrete this peptide in response to a physio-
logical challenge with glucose [1,2]. Moreover, when
transplanted into diabetic mice these cells can lower
blood glucose levels to the normal range [2]. Further, Fer-
ber et al. [9] has recently showed that adenovirus-medi-
ated in vivo transfer of the PDX-1 transgene to the mouse
liver results in the conversion of a hepatocyte subpopula-
tion to the beta cell phenotype. Ferber also showed that
this population of trans-differentiated liver cells was
induced to produce the prohormone convertases PC1/3
and PC2 leading to complete processing of proinsulin.
The amount of insulin produced was sufficient to amelio-
rate streptozotocin-induced hyperglycaemia in the mice.
For this gene therapy approach to be viable, the insulin
producing liver cells must not be destroyed by the
immune system or else this could lead to liver damage.
This fundamental question has not been addressed by
previous studies with (pro)insulin producing hepatocytes
as diabetes in these models was induced chemically rather
than by autoimmune means [6-9]. The autoimmune
destruction of insulin-producing hepatocytes is a possibil-
ity since hepatocytes express major histocompatibility
complex (MHC) class I molecules [10], and constitutively
express Fas [11], moreover the liver cells have antigen pre-
senting activity [12] and are attacked in autoimmune dis-
eases such as chronic active hepatitis. Furthermore
(pro)insulin appears to be an autoantigen in the develop-
ment of type 1 diabetes [13,14]. Evidence for this comes
from the presence insulin and Glutamic Acid Decarboxy-
lase (GAD) autoantibodies in the sera of people with pre-
diabetes [13]. It also comes from studies that show that
diabetes can be adoptively transferred to normoglycaemic
mice by the introduction of insulin-specific T cell clones
[14]. These data taken together suggest that hepatocytes
which produce (pro)insulin might be targeted and
destroyed by the same autoimmune processes responsible
for the destruction of pancreatic β cells.
To address this question in vivo, transgenic Non-Obese
Diabetic (NOD) mice that express insulin in the liver were
created using the Phosphoenolpyruvate Carboxykinase
(PEPCK) promoter [15] to direct expression of the mouse
insulin I gene. This promoter had previously been used to
create a transgenic C57BL/6 human insulin secreting
mouse line with hepatic insulin expression [7]. However
these mice do not develop autoimmune diabetes and
would be unsatisfactory to address the issue of insulin
autoantigenicity.
The liver of the transgenic PEPCK-Ins NOD mice were
characterised with respect to insulin mRNA transcription,
(pro)insulin content and (pro)insulin release. The blood
sugar levels of the animals were monitored and the livers




The PEPCK promoter was generously donated by Dr R. W.
Hanson (Case Western Reserve University, Cleveland,
Ohio, USA). DNA modifying enzymes and competent
bacteria for transformation were purchased from Promega
(Madison, Wisconsin, USA). RPMI 1640, α-MEM and
fetal bovine serum (FBS) were purchased from Trace Bio-
sciences (Castle Hill, Sydney, Australia). Hybond-N+
nylon membrane for the Southern Blot and ribonuclease
protection assay (RPA) was from Amersham International
(Bucks, UK). Human insulin and rat insulin standards for
the in-house radioimmunoassay (RIA) were obtained
from Novo Nordisk (Bagsvaerd, Denmark).
Transient transfection of HEPG2 cells
The transfection of the HEP G2 cells with the PEPCK-Ins
transgene was carried out using Lipofectamine (Gibco-
BRL, Madison, Wisconsin, USA). Cells were trypsin har-
vested and seeded 24 hr prior to transfection at a density
of 200,000 cells/well in 24 well tissue culture plates (Bec-
ton Dickinson, New Jersey, USA) to achieve 60–80% con-
fluence at the time of transfection. 10µl of Lipofectamine
was added to 300µl of serum free media and incubated at
room temperature for 30 minutes. After the incubation,
300µl of DNA solution (3–4µg) was added and the
lipid:DNA complex solution incubated at room tempera-
ture for 15 minutes. The cells were washed once with 1 ml
of serum free medium prior to the transfer of 300µl of the
lipid:DNA complex solutions to the cells. The cells were
then incubated for 5 h at 37°C in an air incubator. The
DNA/lipid complex media was removed and replaced
with 2 mL of α-MEM 10% FBS which contains Antimy-
cotic and Antibiotic solution (10µL/mL) (Sigma, St Louis,
Missouri, USA). In addition, for the PEPCK-Ins transgene,
a final concentration of 100 nM glucagon was added to
the media to upregulate the PEPCK promoter. The cells
were incubated at 37°C in an air incubator for 48–60 hr.
After the incubation, the conditioned culture medium was
collected and assayed for mouse (pro)insulin.
Insulin Radioimmunoassay (RIA)
(Pro)insulin was measured by an in-house RIA using rat
insulin standard (Novo Nordisk Laboratories, Bagsvaerd,
Denmark). The lowest value on the rat insulin standardJournal of Autoimmune Diseases 2004, 1:3 http://www.jautoimdis.com/content/1/1/3
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curve used in the assay was 0.25 ng/ml. The intra and inte-
rassay coefficients of variance were <5% and 10%
respectively.
Generation of transgenic mice
To direct the expression of the mouse insulin I gene to the
liver of the transgenic mice, the 5' flanking sequences (-
460 bp to +73 bp) of the rat PEPCK gene [15] were used
to drive the expression of the genomic mouse insulin I
gene (-25 bp to +557 bp) [16]. The construct was digested
with Xba I and Pst I (Fig 1A) and the PEPCK-Ins transgene
was isolated from the agarose gel using the Supelco Gen-
Elute Spin Column (Sigma, St Louis, Missouri, USA).
Standard procedures were followed to generate transgenic
mice [17]. Fertilized mouse eggs were flushed from the
oviducts of superovulated NOD mice 6–8 h after ovula-
tion. Male pronuclei of the fertilized eggs were injected
with 2pl of the DNA solution (2 ng/µl) and the embryos
that divide to the 2 cell stage were implanted in the ovi-
ducts of pseudopregnant mice. After birth the animals
were tested for the presence of the transgene by PCR and
Southern blot of the DNA from tail tip samples taken after
weaning at 3 weeks of age.
Treatment of the animals
The mice were fed ad libitum with a standard diet and
kept under a light-dark cycle of 12 h in compliance with
the animal ethics of our institution. The facilities used to
breed and maintain the mice were specific pathogen free,
with air passaged through a HEPA filter. The transgenic
PEPCK-Ins NOD mice and the wild type littermates were
monitored for natural development of diabetes. The dia-
betic PEPCK-Ins transgenic NOD mice were maintained
by daily insulin injections and sacrificed 4 weeks after
they became diabetic.
Blood glucose measurements of mice
Blood glucose levels of the wild type as well as the trans-
genic NOD mice were performed using the Medisense
Precision QID Blood Glucose Sensor System (Bedford,
Massachusetts, USA). The mice were bled by pricking the
tail vein and 5µl of the blood placed on to the Precision
Plus blood glucose electrode. A mouse was classified as
being diabetic if a reading of ≥ 15 mmol/l was obtained
on more than one occasion.
Insulin mRNA analysis
The total RNA from liver and pancreas was isolated using
TRIzol (Life Technologies, Grand Island, New York, USA)
[18]. The detection of mouse insulin I mRNA by RT-PCR
was performed using Superscript II RNase H- Reverse Tran-
scriptase from GibcoBRL (Grand Island, New York, USA)
to synthesize the first strand cDNA as recommended by
the manufacturer. The cDNA sample was then used as a
template in PCR amplification (30 cycles) using primers
specific for mouse insulin I mRNA. The sequence of prim-
ers used were:
(Forward) TAA CCC CCA GCC CTT AGT GAC CAG CTA
TAA
(Reverse) AAA GTT TTA TTC ATT GCA GAG GGG TGG
GGC
The PCR products were run on a 1.2% Tris Acetate EDTA
agarose gel, photographed and analysed using the Gel
Doc 1000 system (Biorad, Hercules, California, USA).
Insulin mRNA in the samples was also visualised using
the ribonuclease protection assay (RPA) method. The
plasmid used as the template to transcribe the riboprobe
for mouse insulin I was a generous gift from Chirgwin J.
M. (San Antonio, Texas, USA). The Digoxigenin (DIG)
labelled insulin riboprobe was synthesized by the in vitro
transcription method using the DIG RNA labeling kit
(SP6/T7) from Boehringer Mannheim (Mannheim, Ger-
many), which utilises DIG-dUTP, according to the manu-
facturer's recommendations.
Hybridisation and RNase treatment were performed using
the RPA II kit from Ambion according to the manufac-
turer's recommendations. Next the samples were loaded
and run on a 6% polyacrylamide/8 M urea denaturing
mini-gel in Tris borate EDTA buffer. The RNA bands on
the gel were transferred onto a nylon membrane by using
an electro-gel transfer apparatus and the membrane was
fixed by using an UV cross linker (Hybaid, UK).
For the visualisation of the RNA bands on the nylon mem-
brane, the DIG Wash and Block Buffer Set and the DIG
Chemiluminescent Detection Kit, both of which were pur-
chased from Boehringer Mannheim, were used. The mem-
brane was then exposed to a standard Kodak X-ray film for
30 minutes. The film was subsequently analysed using the
Gel Doc 1000 system.
Organ culture
Pancreatic and hepatic tissue organ cultures were per-
formed using organ culture dishes from Becton Dickinson
(New Jersey, USA) [19]. Briefly, the organs were taken
from mice, and an aliquot of 10–30 mg removed from
each organ. The tissue was then diced into 1 mm3 explants
and spread on a filter paper placed on a sterile wire grid in
the inner well of the organ culture dish such that the tissue
was exposed to air above and the RPMI 1640 10% FBS
medium below. Sterile saline was placed in the outer well
to maintain a humidified environment. The tissue in the
organ culture dishes were incubated for 24 hr in a humid-
ified 5% CO2 and air incubator at 37°C. Culture superna-
tant from all media changes of respective wells wereJournal of Autoimmune Diseases 2004, 1:3 http://www.jautoimdis.com/content/1/1/3
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A-C. The PEPCK-Ins transgene Figure 1
A-C. The PEPCK-Ins transgene. Schematic representation (A). Example of PCR screening of PEPCK-Ins transgenic mice (B). 
Lanes 1–5 and lanes 10–14 are PCR reactions with genomic DNA extracted from mice that developed from microinjected 
mouse eggs. Primers specific for the PEPCK-Ins transgene were used for lanes 1–9 (30 cycles) while primers specific for mouse 
insulin 1 were used for lanes 10–18 (30 cycles). Lanes 6 and 15 are PCR negative controls (no DNA added). Lanes 7 and 16 are 
PCR reactions to demonstrate the specificity of the primers used (wild type NOD mouse DNA added). Lanes 8, 9, 17 and 18 
are half copy spiked and plasmid controls respectively (positive controls). Example of Southern Blotting for the PEPCK-Ins 
transgene (C). Lane 1 One copy spiked sample (100 ng Balb/c genomic DNA + 102fg PEPCK-Ins plasmid), lane 2 genomic DNA 
from tail tip of F2 PEPCK-Ins mouse, lanes 3 and 4 are DNA from pups which died before weaning and lanes 5–7 are DNA 
from still born pups. Each lane was loaded with 15µg of genomic DNA that was digested with Xba I and Pst I to release the 
transgene.
A      
            PEPCK promoter (530bp)          Mouse insulin 1 + Poly A sequence (600bp) 
          AATAAA 
Xba I                                                 Bgl II                                                           Pst I 
B
         1      2      3     4     5     6      7      8     9     10    11   12   13   14    15    16    17   18 
              Genomic mouse Ins I 
         PEPCK-Ins Tg               
C
               1                 2                3                 4                 5                 6                 7 
    Heterozygous pups    Stillborn pups
     Single Copy      Het  died before weaning    (Homozygous)      
        Tg CTL       mouse         Journal of Autoimmune Diseases 2004, 1:3 http://www.jautoimdis.com/content/1/1/3
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pooled separately and kept at -20°C until the RIA was per-
formed. The results were expressed per mg of tissue.
(Pro)insulin content
(Pro)insulin was extracted by homogenising a weighed
sample of liver or pancreas in acid-ethanol (solution of
0.18 mol/l HCl in 70% ethanol) and incubating overnight
at 4°C. The next day, the samples were spun down and the
supernatant removed. The (pro)insulin content was deter-
mined by RIA and the results expressed per mg tissue.
In situ hybridisation of (pro)insulin mRNA
To detect the transcription expression of (pro)insulin, in
situ hybridisation (ISH) was performed on pancreatic and
liver tissues of diabetic transgenic PEPCK-Ins NOD mice
and diabetic wild type NOD mice using a modification of
a previously described method (20). Briefly, 4µm thick
paraffin sections were deparaffinized with xylene, ethanol
and air dried. The sections in 0.01 mol/l citric buffer, pH
6.0 were then treated with microwave irradiation for 10
min. Following this procedure the sections were treated
with proteinase K (Invitrogen, Carlsbad, CA, USA) 1µg/ml
for 15 min at 37°C. They were washed 3 times with phos-
phate buffered saline for 5 min and dried with ethanol.
The sections were then hybridized with [35]-S-labelled
riboprobes (1µg/ml) overnight at 57°C. The [35]-S-
labelled riboprobes were synthesized by in vitro transcrip-
tion (SP6/T7) incorporation of [35]-S-dUTP using RNA
polymerase (Roche, Mannheim, Germany). The template
used was mouse insulin I cDNA that was generously
donated by Chirgwin JM (San Antonio, Texas, USA). The
hybridisation buffer consisted of a 25µl hybridisation
cocktail (labelled riboprobe 500,000 cpm/section, 50%
formamide, 0.1% SDS, 0.1% sodium thiosulfate, 0.1 mol/
l DTT, 0.3 mol/l NaCl, 20 mmol/l Tris-HCl [pH 7.5], 2
mmol/l EDTA, 20% dextran sulphate, 0.02% sheared
salmon sperm DNA, 0.1% total yeast RNA, 0.02% yeast
tRNA, 1 × Denhardt's solution). After hybridisation, the
slides were soaked in 2X standard saline citrate (SSC),
rinsed with deionised water and then treated with RNase
A (20µg/ml) for 30 min at room temperature. High strin-
gency washes were then performed on the slides with
2XSSC followed by 0.2XSSC. The slides were then dried by
ethanol, air dried for 20 min and the results viewed by
NBT2 emulsion autoradiography (Kodak, Rochester, New
York). For controls, sense-probe instead of anti-sense was
used for hybridisation. The photos were taken using the
Olympus IX70 microscope (Melville, New York) with a
dark field condenser.
Histochemistry
Sections of the liver and pancreas from the transgenic
mice were washed twice in Phosphate Buffered Saline
(PBS), fixed in 10% formalin overnight and embedded
into paraffin. Consecutive 5µm sections were cut and
placed on poly-L-lysine-coated slides. After dewaxing and
serial alcohol rehydration, the tissue sections were treated
with H2O2, and then incubated in PBS containing 10%
goat serum or 1% BSA for 20 minutes at room tempera-
ture to block nonspecific binding.
For insulin staining, primary insulin antibody (Dako Cor-
poration, Via Real, Carpinteria, California, USA) at
1:1250 was added and the sections were incubated over-
night. The next morning the sections were washed in PBS
and incubated with anti-guinea pig IgG (1:400) at room
temperature for 20 minutes. Thereafter the sections were
washed again with PBS, and biotinylated anti-rabbit /
mouse antibody added to the sections for 15 minutes fol-
lowed by streptavidin-peroxidase conjugate for a further
15 minutes. Finally, the sections were treated with sub-
strate-chromogen AEC. A standard concentration (0.1%)
of haematoxylin was added as a counterstain. The primary
antibody was omitted for the negative control. The hae-
matoxylin and eosin staining of sections was performed
automatically by the Jung Autostainer XL machine (Leica,
New Jersey, USA).
Statistical analysis
The log rank-test was used to determine whether the
occurrence of diabetes in the transgenic mice was signifi-
cantly different from the wild type NOD mice. The non-
parametric t-test (Mann-Whitney U test) was used to
determine whether the blood glucose levels of the diabetic
transgenic and wild type NOD mice were significantly
different.
Results
Transient transfection of HEP G2 with PEPCK-Ins
To confirm that the PEPCK-Ins transgene (Figure 1A) was
functional, 3–4µg of the transgene was transfected into
the human hepatoma cell line HEP G2. After the transfec-
tion, the cells were incubated in α-MEM supplemented
with 10% FBS. Glucagon was added to upregulate the
PEPCK promoter expression at a final concentration of
100 nmol/l for 24 hr. At the end of the incubation period,
the conditioned culture medium was positive for rodent
insulin at a concentration of 0.90 ± 0.04 ng/200,000 HEP
G2 cells (n = 8).
Generation of transgenic mice
From a series of two microinjections, 43 mice were
obtained of which 4 were positive for the PEPCK-Ins
transgene when analysed by PCR (Figure 1B) and South-
ern blot (Figure 1C). Two of the 4 transgenic founder mice
were found to have established germline transmission of
the transgene. From the Southern blot analysis, these mice
have only a single copy of the transgene (Figure 1C).Journal of Autoimmune Diseases 2004, 1:3 http://www.jautoimdis.com/content/1/1/3
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Transcription of insulin I mRNA in the liver
Of the two lines only one was found to transcribe insulin
mRNA in the liver, as determined by mouse insulin I RT-
PCR (Figure 2A) and mouse insulin I Ribonuclease Pro-
tection Assay (RPA) (Figure 2B). No insulin mRNA was
detected in the second line despite documented germline
transmission of the transgene. The transgenic mice
appeared healthy and active, and were normoglycaemic.
The blood glucose levels were 6.0 ± 1.1 mmol/l (n = 20)
as compared to 6.5 ± 0.5 (n = 20) for wild type littermates.
Production of (pro)insulin from liver cells
The ability of the liver cells from PEPCK-Ins positive trans-
genic mice to produce (pro)insulin was examined on liver
removed from mice that had been sacrificed. Ideally pro-
duction of (pro)insulin from the liver would be sought in
vivo. This was not possible since any (pro)insulin released
from the liver would be indistinguishable from that
secreted from pancreatic β cells. Two methods were used
to analyse if (pro)insulin was produced from liver tissue
removed from the mice. The liver was both extracted for
its hormonal content, and placed in organ culture with
analysis of the conditioned culture medium for (pro)insu-
lin. In both cases, (pro)insulin was measurable. The
(pro)insulin content was 0.5 ± 1 ng/mg (n = 5), which is
equivalent to 8% of the (pro)insulin content of the pan-
creas (Table 1) on a weight to weight basis. Organ culture
of explants in the presence of 100 nM glucagon resulted in
release of 3.4 ± 1 ng/mg (pro)insulin per day, which is
23% of that produced by cultured pancreatic explants. No
(pro)insulin could be found either in liver extracts or from
cultured liver explants taken from wild type NOD mice.
These results show that there was translation of (pro)insu-
lin from preproinsulin mRNA in the liver of transgenic
mice. The amount of (pro)insulin present in the liver cells
was too small for it to be detected immunohistochemi-
cally (data not shown).
In situ hybridisation of (pro)insulin mRNA
In situ hybridisation confirmed the presence of (pro)insu-
lin mRNA in the pancreatic and liver sections of diabetic
PEPCK-Ins transgenic mice (Figure 3A and 3C) but not in
the liver section of the wild type NOD mice (Figure 3E).
The (pro)insulin mRNA was localised to the hepatocytes
of the diabetic PEPCK-Ins transgenic mice which appear
to be evenly distributed throughout the liver section (Fig-
ure 3C). The sense control sections were negative (Figure
3B,3D and 3E).
Occurrence of diabetes in transgenic mice
One out of 14 males (7%) and four out of 25 females
(16%) of the F1 and F2 progeny of the PEPCK-Ins trans-
genic NOD mice became diabetic (Figure 4). The age at
which this occurred was 20–25 weeks. Among the wild
type NOD mice in our colony, 5 males out of 45 (11%)
and 22 out of 51 females (43%) became diabetic (Figure
4), at 19–28 weeks of age. The mice were followed for a
total of 15 months but no other transgenic mice became
diabetic while 55% of the NOD females became diabetic.
The incidence of diabetes in the transgenic PEPCK-Ins
NOD females (16% diabetic at 30 weeks) differs signifi-
cantly from the incidence of diabetes in the wild-type
NOD females (43% diabetic at 30 weeks) as determined
by the log-rank test (chi squared value 16.1, P < 0.001).
The overall incidence of diabetes in the transgenic PEPCK-
Ins NOD mice (13%) was also significantly lower com-
pared to the wild type (28%) NOD mice as determined by
the log-rank test (chi squared value 18.7, P < 0.001). The
blood glucose levels of the diabetic transgenic NOD
PEPCK-Ins mice (24.8 ± 1.9 mmol/l) were also signifi-
cantly lower than those of the diabetic wild type NOD
mice (>33 ± 2.1 mmol/l) as determined by the Mann
Whitney U test, U = 32 and P = 0.004.
The livers of the diabetic transgenic mice were examined
histologically to determine if there was cellular infiltra-
tion and destruction of hepatocytes. This was not so, the
liver having a normal architecture with no evidence of
necrosis (Figure 5). In contrast, there was a cellular infil-
trate in the islets of the diabetic (Figure 6A) but not nor-
moglycaemic transgenic mice (Figure 6B)
Immunohistochemical staining for (pro)insulin showed a
reduced number of β cells (Figure 6C) compared to nor-
moglycaemic littermates (Figure 6D).
Next, the (pro)insulin content of the liver of the diabetic
mice was determined. This was similar to that from the
liver of normoglycaemic transgenic mice (Table 1).
(Pro)insulin release from cultures of liver cells was meas-
ured, and again found to be similar to that from the liver
cells of non-diabetic transgenic mice (Table 1). However,
as expected, the (pro)insulin content of the pancreas of
diabetic transgenic mice was lower than that of normogly-
caemic transgenic or wild type mice (Table 1). Indeed, the
level was so low as to be comparable to that seen in the
liver of either normoglycaemic or diabetic transgenic
mice. The amount of (pro)insulin released from pancre-
atic explants from the diabetic transgenic mice was too
low to be detected.
Discussion
At the end of the study, 5 heterozygous transgenic PEPCK-
Ins NOD mice had become diabetic. Nevertheless, pre-
proinsulin mRNA was localised to the hepatocytes by in
situ hybridisation and was detected in total RNA extracts
of the livers of these transgenic mice by both RT-PCR and
RPA. (Pro)insulin was detected in acid ethanol extracts of
the livers from the transgenic mice by RIA. Furthermore,
(pro)insulin was released from explants of transgenic liverJournal of Autoimmune Diseases 2004, 1:3 http://www.jautoimdis.com/content/1/1/3
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A-B. Mouse insulin 1 mRNA Figure 2
A-B. Mouse insulin 1 mRNA. RT-PCR (A). Lanes 1A-6A are RT-PCR reactions using primers specific for mouse insulin 1 
mRNA (30 cycles). Lanes 1B-6B are RT-PCR reactions using primers specific for mouse GAPDH mRNA (30 cycles). Lanes 1–4 
are total RNA from the liver of progeny from founder T645-18, lane 5 is total RNA from the liver of progeny from founder 
T647-2 and lane 6 total RNA from the pancreas of progeny from founder T645-18. RPA for mouse insulin 1 mRNA (B). Lane 
1 pancreatic total RNA, lane 2 liver total RNA from T647-2 progeny and lanes 3–7 liver total RNA from T645-18 progeny.
A 
                                      1    2    3    4    5    6 
B
         1             2            3            4            5             6            7 
A 
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Table 1: (Pro)insulin content of and release from pancreatic and hepatic tissue of transgenic and wild type NOD mice.
PANCREAS LIVER






(Pro)insulin release in the 
presence of 100 nmol/l 
glucagon (ng/mg tissue/ 
day)
Normoglycaemic 
transgenic (n = 5)
6.3 ± 0.8 15.8 ± 1.6 0.5 ± 0.1 3.4 ± 1.0
Normoglycaemic wild type 
(n = 3)
6.3 ± 1.0 15.2 ± 2.3 ND ND
Diabetic transgenic (n = 5) 0.5 ± 0.1 (n = 3; 2 ND) ND (n = 3) 0.6 ± 0.2 (n = 5) 3.6 ± 0.3 (n = 3)
ND – not detectable (<0.025 ng/mg tissue)
Data expressed as X ± SD.
A-F. In-situ hybridisation Figure 3
A-F. In-situ hybridisation. Pancreatic islets from a diabetic transgenic mouse illustrating insulitis, (A) antisense and (B) sense. 
Transgenic liver from a diabetic transgenic mouse (C) antisense and (D) sense. Wild type liver from a diabetic NOD mouse (E) 





Wt Liver Tg Liver Tg Islets Insulitis
A
BE D
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placed in organ culture. These results indicate that the
liver cells from these transgenic PEPCK-Ins NOD mice did
synthesise and produce (pro)insulin.
Histological examination of the livers of the diabetic
transgenic mice showed no infiltration of the liver by
immune cells even though insulitis was observed in the
pancreatic sections. This indicates that hepatic insulin
production did not cause the development of tolerance to
insulin in these PEPCK-Ins transgenic NOD mice. The
lack of infiltration of immune cells in the livers of the dia-
betic transgenic mice also suggests that the mouse insulin
I mRNA transcribing hepatocytes were not targeted or
destroyed by the immune system. In addition, as the
transgenic mice were sacrificed 4 weeks after the onset of
diabetes, this reduces the possibility of delayed destruc-
tion of the (pro)insulin expressing hepatocytes. During
this time, hepatic insulin expression was at least equal to
that found in the pancreas. At the apparently low levels of
transgene expression, these results suggest that (pro)insu-
lin is not targeted by the immune system in this transgenic
PEPCK-Ins mouse model superimposed on the autoim-
mune diabetes model of the NOD mouse. Likewise, Lipes
et al reported that when pituitary cells in transgenic NOD
mice were made to produce insulin, the cells were not tar-
geted by the immune system even though the pancreatic β
cells were. No cellular infiltrate also was shown when the
pituitary cells that produced (pro)insulin were taken out-
side the blood brain barrier and transplanted beneath the
renal capsule of NOD mice [21]. Our data and those of
Incidence of diabetes in F1 and F2 PEPCK-Ins transgenic NOD mice versus wild type F1 and F2 NOD mice Figure 4
Incidence of diabetes in F1 and F2 PEPCK-Ins transgenic NOD mice versus wild type F1 and F2 NOD mice. PEPCK-Ins NOD 
males total n = 14, PEPCK-Ins NOD females n = 25, wild type NOD males n = 45 and wild type NOD females n = 51.






























 PEPCK Ins NOD females
 NOD Males
 NOD Females
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Lipes et al suggest that autoimmune destruction of
(pro)insulin producing cells in the NOD mouse is specific
to the islets.
The blood glucose levels of the diabetic transgenic NOD
PEPCK-Ins mice (24.8 ± 1.9 mmol/l) were significantly
lower (P = 0.004) than those of the diabetic wild type
NOD mice (>33 ± 2.1 mmol/l). This is consistent with
some (pro)insulin being released from the liver. These
results are in agreement with those of Valera et al in which
the majority of their high copy number PEPCK human
insulin C57BL/6 mice also became diabetic when injected
with streptozotocin despite the constitutive release of
human (pro)insulin from the livers of the mice (7). Simi-
larly, the transgenic mice which Valera et al made diabetic
by streptozotocin injections also had lower blood glucose
levels compared to the diabetic wild type NOD mice sug-
gesting that the constitutive hepatic insulin release low-
ered the blood glucose levels of the diabetic mice but not
to normal. This lack of therapeutic effect could be due to
the fact that the PEPCK promoter is induced by glucagon
and cyclic AMP. The high glucose levels in the diabetic
transgenic mice might have resulted in the inhibition of
endogenous glucagon release and thus shutting down
(pro)insulin production in the liver.
However it is possible that in some of our transgenic mice,
enough (pro)insulin was produced to prevent diabetes.
This would explain the significantly lower incidence of
diabetes in the transgenic PEPCK-Ins (13%) compared to
the wild type (28%) NOD mice (P < 0.001). One possibil-
ity is a protective effect of insulin, whether by allowing
exhausted beta cells to rest or by altering the makeup of
the T cells in the pancreas destroying the β cells there. The
first reason was the basis for the large North American trial
in pre-diabetic people in the late 90's with small doses of
parenteral insulin [22]. The second reason was the basis
for the large North American trial in pre-diabetic people
in the very late 90's with oral insulin [23].
It is possible that a critical amount of (pro)insulin needs
to be produced for an autoimmune effect to be observed.
The (pro)insulin content of the transgenic liver cells in
normoglycaemic mice was much lower than that of a pan-
creatic β cell and was also lower than that in the liver of
PEPCK-human insulin C57BL/6 transgenic mice pro-
duced by Valera et al [7]. (Pro)insulin was not detected
immunohistochemically in the liver of our PEPCK-Ins
transgenic mice, whereas it was in the liver of Valera's
transgenic mice. Attempts by us to increase production of
(pro)insulin by producing homozygous mice failed, with
all mice being stillborn (Figure 1C). This might be
because of transient upregulation of the PEPCK gene at
birth [24], resulting in increased production of (pro)insu-
lin that caused hypoglycaemia. Alternatively, it could be
due to a transgene integration effect where the transgene
disrupted a vital gene; with a double copy deletion being
lethal.
Another possible explanation for the lack of an autoim-
mune effect is that presentation of insulin peptides by
hepatocytes might be limited by the ability of the liver
cells to cleave proinsulin. The enzymes responsible for
this in the β cell, prohormone convertases (PC) 1/3 and
PC2, are absent from normal liver cells, but the
endopeptidase furin is present [25]. Cleavage of
proinsulin by furin however would require genetic modi-
fication of the peptide [8].
Staining of the liver of diabetic transgenic PEPCK-Ins mice  with haematoxylin and eosin Figure 5
Staining of the liver of diabetic transgenic PEPCK-Ins mice 
with haematoxylin and eosin. (Black Bar = 20µm).Journal of Autoimmune Diseases 2004, 1:3 http://www.jautoimdis.com/content/1/1/3
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A-D. Haematoxylin and eosin, and insulin staining of pancreatic sections from transgenic PEPCK-Ins NOD mice Figure 6
A-D. Haematoxylin and eosin, and insulin staining of pancreatic sections from transgenic PEPCK-Ins NOD mice. H & E staining 
of a pancreatic islet from a diabetic transgenic mouse illustrating insulitis (A), and from a normoglycaemic transgenic mouse 
(B). Insulin staining of a pancreatic islet from a diabetic transgenic mouse showing few remaining β cells (C) and from a normo-
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In summary, we have shown that transgenic NOD mice
that produce (pro)insulin in their liver do not develop cel-
lular infiltration of their liver when autoimmune destruc-
tion of pancreatic β cells occur. Furthermore the
expression of (pro)insulin in hepatocytes is insufficient to
prevent development of diabetes in NOD mice. These
results offer hope that eventually liver cells, or a subpop-
ulation of them, may be of value as a therapy for type 1
diabetes.
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